Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
Objective To assess the association between the use of sodium glucose cotransporter 2
(SGLT2) inhibitors and seven serious adverse events of current concern. Design Register …
(SGLT2) inhibitors and seven serious adverse events of current concern. Design Register …
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
Objective To assess the association between use of sodium-glucose co-transporter 2
(SGLT2) inhibitors and risk of serious renal events in data from routine clinical practice …
(SGLT2) inhibitors and risk of serious renal events in data from routine clinical practice …
Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
B Pasternak, P Ueda, B Eliasson, AM Svensson… - bmj, 2019 - bmj.com
Objective To investigate the cardiovascular effectiveness of sodium glucose cotransporter 2
(SGLT2) inhibitors in routine clinical practice. Design Cohort study using data from …
(SGLT2) inhibitors in routine clinical practice. Design Cohort study using data from …
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
Objective To compare the risk of cardiovascular events between sodium glucose
cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors among …
cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors among …
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
Objective To estimate the association between the use of sodium glucose co-transporter-2
(SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies. Design …
(SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies. Design …
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network …
Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews
R Pelletier, K Ng, W Alkabbani… - … Advances in Drug …, 2021 - journals.sagepub.com
Background: Multiple published quantitative systematic reviews have reported on adverse
events associated with the use of sodium glucose co-transporter 2 (SGLT-2) inhibitors in …
events associated with the use of sodium glucose co-transporter 2 (SGLT-2) inhibitors in …
A safety update on sodium glucose co‐transporter 2 inhibitors
D Fitchett - Diabetes, Obesity and Metabolism, 2019 - Wiley Online Library
Sodium glucose co‐transporter 2 inhibitors (SGLT2is) are the first class of glucose lowering
agent to be shown to reduce cardiovascular events. They are generally well tolerated with …
agent to be shown to reduce cardiovascular events. They are generally well tolerated with …
Sodium‐glucose co‐transporter‐2 inhibitors and major adverse limb events: a trial‐level meta‐analysis including 51 713 individuals
CY Huang, JK Lee - Diabetes, Obesity and Metabolism, 2020 - Wiley Online Library
Aim To analyse large‐scale cardiovascular outcome trials of sodium‐glucose co‐transporter‐
2 (SGLT‐2) inhibitors to evaluate whether there are safety concerns with respect to major …
2 (SGLT‐2) inhibitors to evaluate whether there are safety concerns with respect to major …
Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
TM Caparrotta, AM Greenhalgh, K Osinski, RM Gifford… - Diabetes Therapy, 2021 - Springer
Introduction Sodium–glucose co-transporter 2 inhibitors (SGLT2is) are licensed for the
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …
treatment of type 2 diabetes (T2D) and more recently for heart failure with or without …